Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | IL6ST | P40189 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 8/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | MTOR | P42345 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155682 | 1.00 | PPARA (0.37) | PPARAABHD6DAGLAIL6STAGTR2 | |
| SCHEMBL18017398 | 0.87 | ALDH1A1 (0.33) | IL6STIDH1 | |
| SCHEMBL1155529 | 0.86 | ABHD6 (0.35) | PPARAABHD6DAGLAIL6STCSNK2B | |
| SCHEMBL1155527 | 0.86 | ABHD6 (0.35) | PPARAABHD6DAGLAIL6STCSNK2B | |
| SCHEMBL9962996 | 0.83 | AGTR2 (0.35) | PPARAIL6STAGTR2CSNK2BCSNK2A1 | |
| SCHEMBL9962987 | 0.81 | IL6ST (0.44) | PPARAIL6STAGTR2CSNK2BCSNK2A1 | |
| SCHEMBL13654970 | 0.78 | PPARA (0.37) | PPARAIL6STCSNK2BCSNK2A1IDH1 | |
| SCHEMBL16630236 | 0.76 | CYP11B2 (0.37) | — | |
| SCHEMBL9962999 | 0.75 | IDH1 (0.37) | PPARAIL6STAGTR2IDH1FAAH | |
| SCHEMBL1155471 | 0.75 | FAAH (0.33) | IL6STAGTR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501786-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2274296-B1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | PPARA 286/4885ABHD6 3459/4885DAGLA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.